Promotion of a Mediterranean Diet Alters Constipation Symptoms and Fecal Calprotectin in People with Parkinson’s Disease: A Randomized Controlled Trial
Nutrients · 02.09.2024 · 16 (17) · 2946
DOI: 10.3390/nu16172946 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 02.09.2024. Verfasst von Carley Rusch und 8 weiteren Autor:innen. Beteiligte Einrichtung: Food Science and Human Nutrition Department, Center for Nutritional Sciences, University of Florida, Gainesville, FL 32611-0370, USA. Hauptthemen laut MEDLINE: Constipation, Leukocyte L1 Antigen Complex, Feces, Diet, Mediterranean. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: USDA National Institute of Food and Agriculture Hatch, Fixel Family Foundation, Lauren and Lee Fixel Family Foundation.
Abstract (Originalsprache)
Parkinson’s disease is associated with gastrointestinal (GI) dysfunction, including constipation symptoms and abnormal intestinal permeability and inflammation. A Mediterranean diet (MediDiet) may aid in disease management. This parallel, randomized, controlled trial in people with Parkinson’s (PwP) and constipation symptoms compared a MediDiet against standard of care on change in constipation symptoms, dietary intake, and fecal zonulin and calprotectin concentrations as markers of intestinal permeability and inflammation, respectively. Participants were randomized to either standard of care for constipation (control; n = 17, 65.1 ± 2.2 years) or a MediDiet plus standard of care (n = 19, 68.8 ± 1.4 years) for 8 weeks. Constipation scores decreased with both interventions (p < 0.01), but changes from baseline were not different between groups (MediDiet, −0.5 [−1.0, 0]; control, −0.8 [−1.0, 0.2]; median [25th, 75th]; p = 0.60). The MediDiet group had a higher intake of dietary fiber at week 4 than the control group (13.1 ± 0.7 g/1000 kcal vs. 9.8 ± 0.7 g/1000 kcal; p < 0.001). No differences in fecal zonulin were observed between groups (p = 0.33); however, fecal calprotectin tended to be lower in the MediDiet group at week 8 (45.8 ± 15.1 µg/g vs. 93.9 ± 26.8 µg/g; p = 0.05). The MediDiet and standard interventions reduced constipation symptoms; however, the MediDiet provided additional benefit of increased dietary fiber intake and less intestinal inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Food Science and Human Nutrition Department, Center for Nutritional Sciences, University of Florida, Gainesville, FL 32611-0370, USA.
- Department of Neurology, Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL 32610-0236, USA.
- Department of Epidemiology, Emerging Pathogens Institute, University of Florida, Gainesville, FL 32610-0009, USA.
ORCID-Profile: Carley Rusch, Volker Mai, Tamara Stiep, Adolfo Ramirez-Zamora, Bobbi Langkamp-Henken
Förderung
- USDA National Institute of Food and Agriculture Hatch
- Fixel Family Foundation
- Lauren and Lee Fixel Family Foundation
Zitieren
APA
Rusch, C., Beke, M., Nieves, C., Mai, V., Stiep, T., Tholanikunnel, T., Ramirez-Zamora, A., Hess, C. W., & Langkamp-Henken, B. (2024). Promotion of a Mediterranean Diet Alters Constipation Symptoms and Fecal Calprotectin in People with Parkinson’s Disease: A Randomized Controlled Trial. Nutrients, 16(17), 2946. https://doi.org/10.3390/nu16172946
Vancouver
Rusch C, Beke M, Nieves C, Mai V, Stiep T, Tholanikunnel T, et al. Promotion of a Mediterranean Diet Alters Constipation Symptoms and Fecal Calprotectin in People with Parkinson’s Disease: A Randomized Controlled Trial. Nutrients. 2024;16(17):2946. doi:10.3390/nu16172946
BibTeX
@article{Rusch2024,
author = {Rusch, Carley and Beke, Matthew and Nieves, Carmelo and Mai, Volker and Stiep, Tamara and Tholanikunnel, Tracy and Ramirez-Zamora, Adolfo and Hess, Christopher W and Langkamp-Henken, Bobbi},
title = {Promotion of a Mediterranean Diet Alters Constipation Symptoms and Fecal Calprotectin in People with Parkinson’s Disease: A Randomized Controlled Trial},
journal = {Nutrients},
year = {2024},
volume = {16},
number = {17},
pages = {2946},
doi = {10.3390/nu16172946}
}
EUVIMED